BioMarin Pharmaceutical is a San Rafael, California-based, NASDAQ-listed (ticker: BMRN) global rare-disease biopharmaceutical company that develops and commercialises treatments for serious genetic conditions, with a portfolio anchored by the VOXZOGO achondroplasia franchise, the Enzyme Replacement Therapy (ERT) Metabolic Conditions portfolio (VIMIZIM, NAGLAZYME, ALDURAZYME, BRINEURA, PALYNZIQ), and the newly acquired GALAFOLD and POMBILITI + OPFOLDA franchises that came with the April 27, 2026 close of the Amicus Therapeutics acquisition. The Q2 2026 print shows total revenues of $990 million, up 20% year over year, with VOXZOGO revenue of $253 million (+14% YoY), PALYNZIQ revenue of $135 million (+27% YoY), and the first partial-quarter contribution from the Amicus franchises. The GAAP net income of $45 million (down 81% YoY due to acquisition-related charges) and the non-GAAP net income of $236 million (down 16% YoY) reflect the post-close transition of the Amicus franchises, with the corresponding non-GAAP operating margin of 36.4% reflecting the operating-leverage profile of the combined business.
The investment case is a debate about whether the BioMarin commercial platform is, after the Amicus close, a durable mid-twenties-percent-revenue-growth and high-thirties-percent-non-GAAP-operating-margin rare-disease biopharma that can compound for the next decade, or whether the VOXZOGO franchise is approaching a maturation point, the Amicus integration is more difficult than the Q2 print disclosed, and the post-close operating-margin trajectory is more challenged than the management team has communicated. The bull case is that the combined platform is a diversified rare-disease biopharma with seven commercial franchises, a deep pipeline (VOXZOGO hypochondroplasia, BMN 333, BMN 820, BMN 351), a strong cash flow generation, and a $1B VOXZOGO revenue trajectory for 2026. The bear case is that the Amicus integration is more difficult than the Q2 print disclosed, that the VOXZOGO franchise is approaching a maturation point, and that the post-close operating-margin trajectory is more challenged than the management team has communicated.
The most important event of the Q2 2026 print is the close of the Amicus Therapeutics acquisition on April 27, 2026, which added the GALAFOLD and POMBILITI + OPFOLDA franchises to the consolidated portfolio and is, in our view, the most material strategic action in the company's history. The Q2 2026 print is the first credible look at the post-close operating performance, and the print is, in our view, broadly in line with the management team's stated objective of "accelerating revenue growth, non-GAAP diluted EPS accretion, non-GAAP operating margin expansion, and operating cash flow through the mid-2030s." The implication is that the Amicus close is, in our view, a strategic combination that is broadly on track, and the next several prints are the most important tests of whether the combined platform can deliver the operating-margin expansion and revenue-growth acceleration that the management team has communicated.
A second material event of the Q2 2026 print is the FDA's acceptance of the supplemental New Drug Application (sNDA) for full approval of VOXZOGO in children with achondroplasia, with a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027. The sNDA acceptance is, in our view, a meaningful positive signal that supports the VOXZOGO revenue trajectory, and the corresponding full-approval status would, in our view, support the long-duration VOXZOGO revenue growth. The implication is that the VOXZOGO franchise is, in our reading, the principal value driver for the consolidated platform, and the FDA's sNDA acceptance is a meaningful positive signal that supports the long-duration VOXZOGO revenue growth.
A third material event of the Q2 2026 print is the recent submission of the sNDA for VOXZOGO in hypochondroplasia, with a potential 2027 launch if the FDA approves the application. The hypochondroplasia indication is, in our view, a meaningful expansion of the VOXZOGO franchise, and the corresponding Phase 3 CANOPY-HCH-3 study met its primary endpoint with a statistically significant increase in annualized growth velocity (AGV) at week 52 versus placebo. The implication is that the hypochondroplasia indication is, in our reading, a real growth driver for the VOXZOGO franchise, and the 2027 launch is a meaningful positive catalyst for the long-duration VOXZOGO revenue growth.
A fourth material event of the Q2 2026 print is the addition of BMN 820 (formerly DMX-200) to the portfolio, which is a first-in-class oral CCR2 inhibitor for focal segmental glomerulosclerosis (FSGS) for which BioMarin holds exclusive U.S. commercialisation rights. The BMN 820 addition is, in our view, a meaningful expansion of the late-stage pipeline, and the corresponding clinical-trial programme is, in our view, a meaningful positive signal that supports the long-duration pipeline value. The implication is that the pipeline is, in our reading, a real driver of the long-duration equity story, and the BMN 820 addition is a meaningful positive signal that supports the long-duration pipeline value.